Circ Cardiovasc Interv

Slides:

Advertisements

Similar presentations

Randomised comparison of a novel, ultrathin strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for percutaneous.

Advertisements

Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Smoking Is Associated With Adverse Clinical Outcomes.

Date of download: 7/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: Long-Term Outcomes of Older Diabetic Patients After.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Versus Angiography for Guiding.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:

Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Coronary Anatomy and Stenting Technique.

Date of download: 9/16/2016 Copyright © The American College of Cardiology. All rights reserved. From: 5-Year Clinical Outcomes of the ARTS II (Arterial.

From: Sustained Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Lesions: 2-Year Follow-Up From the Zilver PTX Randomized and Single-Arm.

Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Public Reporting for Percutaneous.

Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Characteristics and Long-Term Outcomes of Percutaneous.

From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Dual Antiplatelet Therapy.

Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE

Figure 1 Flow diagram of systematic review

From: Systematic Review: The Comparative Effectiveness of Percutaneous Coronary Interventions and Coronary Artery Bypass Graft Surgery Ann Intern Med.

Usefulness of Preprocedure High-Sensitivity C-Reactive Protein to Predict Death, Recurrent Myocardial Infarction, and Stent Thrombosis According to Stent.

A Novel Abluminal Coated Sirolimus-Eluting Stent as a Treatment Option for Diabetic Patients: Results from an All-Comers Multi-center Study: the En-ABL.

Supplementary Table 1 Independent Predictors of 2-Year Mortality

12 Month Outcomes in Patients with Diabetes Mellitus Implanted with a Resolute Zotarolimus-eluting Stent: Initial Results from the RESOLUTE Global Clinical.

Copyright © 2013 American Medical Association. All rights reserved.

Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.

Copyright © 2005 American Medical Association. All rights reserved.

Median target vessel revascularization rates per 1000 patient-years of follow-up with bare metal stents (BMS) and first- and second-generation drug-eluting.

Randomised comparison of a novel, ultrathin strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for percutaneous.

Comparison of Outcomes in Patients With Versus Without Diabetes Mellitus After Revascularization With Everolimus- and Sirolimus-Eluting Stents (from the.

Long-term clinical outcome of elderly patients with acute coronary syndrome treated with early percutaneous coronary intervention: Insights from the BASE.

Comparison of Bare-Metal Stents and Drug-Eluting Stents in Coronary Ostial Lesions (from the National Heart, Lung, and Blood Institute Dynamic Registry)

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Circ Cardiovasc Qual Outcomes

Six-month–adjusted survival after aortic valve replacement (AVR) for severe aortic stenosis (AS) stratified by procedure and preoperative ejection fraction.

Circ Cardiovasc Interv

Sex-Related Differences in Fractional Flow Reserve–Guided Treatment

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Unadjusted 3-year cumulative incidence of adverse events after saphenous vein graft (SVG) percutaneous coronary intervention (PCI) with embolic protection.

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Catheter-Based Treatment of Coronary Artery Disease

Multiple arterial grafts improve survival with coronary artery bypass graft surgery versus conventional coronary artery bypass grafting compared with.

Percutaneous coronary invervention versus coronary artery bypass grafting: A meta- analysis Yolba Smit, MD, MSc, Joan Vlayen, MD, Hetty Koppenaal, MD,

Glenn N. Levine et al. JACC 2016;68:

Primary endpoint at 1 year

American College of Cardiology Presented by Dr. Stephan Windecker

Stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: A meta-analysis of comparative studies Hisato Takagi,

Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-year Outcomes of the EVERBIO.

J. Trevor Posenau, MD, Daniel M. Wojdyla, MS, Linda K

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Myocardial Revascularization for Patients With Diabetes: Coronary Artery Bypass Grafting or Percutaneous Coronary Intervention? Serenella Castelvecchio,

Potential conflicts of interest

Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris Toshihiro Fukui,

Hisato Takagi, MD, PhD, Hideaki Manabe, MD, Takuya Umemoto, MD, PhD

Do the EXCEL and NOBLE Trial Results Change Meta-Analysis Findings?

Yin-Shu Chang, MD, Jia-Xiang Wang, MD, PhD, Da-Wei Chang, PhD

To bypass or stent? The changing rules of an advancing game

Revascularization Strategies and Survival in Patients With Multivessel Coronary Artery Disease Noam Fink, MD, Eugenia Nikolsky, MD, Abid Assali, MD,

Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death.

Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial

Glenn N. Levine et al. JACC 2011;58:e44-e122

Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.

Associations between type of MI and incident HF

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Improved Long-Term Survival for Diabetic Patients With Surgical Versus Interventional Revascularization Paul Kurlansky, MD, Morley Herbert, PhD, Syma.

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Presentation transcript:

Circ Cardiovasc Interv Clinical Outcomes According to Diabetic Status in Patients Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents by Anna Franzone, Thomas Pilgrim, Dik Heg, Marco Roffi, David Tüller, André Vuilliomenet, Olivier Muller, Stéphane Cook, Daniel Weilenmann, Christoph Kaiser, Peiman Jamshidi, Lorenz Räber, Stefan Stortecky, Peter Wenaweser, Peter Jüni, and Stephan Windecker Circ Cardiovasc Interv Volume 8(6):e002319 June 4, 2015 Copyright © American Heart Association, Inc. All rights reserved.

Patient flow according to the CONSORT statement. Patient flow according to the CONSORT statement. BMS indicates bare-metal stents; BP-SES, biodegradable polymer sirolimus-eluting stents; CABG, coronary artery bypass grafting; DP-EES, durable polymer everolimus-eluting stents; PCI, percutaneous coronary intervention; and STEMI, ST-segment–elevation myocardial infarction. Anna Franzone et al. Circ Cardiovasc Interv. 2015;8:e002319 Copyright © American Heart Association, Inc. All rights reserved.

Time to event curves for the composite end point target lesion failure and individual components of the primary end point ≤12 months of follow-up in diabetic and nondiabetic patients. Time to event curves for the composite end point target lesion failure and individual components of the primary end point ≤12 months of follow-up in diabetic and nondiabetic patients. A, Target lesion failure; B, cardiac death; C, target-vessel (TV) myocardial infarction; D, clinically indicated target lesion revascularization (TLR). Blue lines indicate biodegradable polymer sirolimus-eluting stent and red lines indicate durable polymer everolimus-eluting stent. Diabetic patients, solid lines; nondiabetic patients, dashed lines. CI indicates confidence interval; DM, diabetes mellitus; and HR, hazard ratio. Anna Franzone et al. Circ Cardiovasc Interv. 2015;8:e002319 Copyright © American Heart Association, Inc. All rights reserved.